COVID-19

T-cell immunity plays a crucial role in controlling COVID-19, especially in individuals who cannot generate antibody responses. Researchers have recently developed a peptide based T cell vaccine candidate CoVac-1. CoVac-1…

In a recent study, scientists used machine learning to create a unique COVID-19 vaccine that targets the stimulation of T cells and is intended to be a pan-variant vaccine...

The antibodies produced by your initial COVID vaccination or infection may adversely impact later booster injections, according to recent research...

Vaccinations that offer long-lasting protection against influenza, coronaviruses, and respiratory syncytial virus (RSV) have been challenging to create; recent research has now investigated the problems and outlined alternatives to better…

In a recent paper, researchers have found that immunisation with the Moderna COVID-19 mRNA vaccine at different times of the day has no effect on the efficacy of the vaccine...

In this study, Ebenig and colleagues were able to come up with a detailed description of what they believe to be the immune-cell mediated mechanisms responsible for inducing Vaccine-associated enhanced…

In a new study, researchers have looked at the primary site of SARS-CoV-2 infection and done T-cell analysis of nasal swab samples to assess immunity following vaccination and infection...

In a recent paper, researchers described the effects and role of CD8+ T-cell responses following vaccination with Ad26.COV2.S (Janssen/Johnson & Johnson) in the response against SARS-CoV-2 infection utilising a rhesus…

Hans-Martin, et al., reported the isolation of monoclonal antibodies from TRIANNI mice, which can be used to provide a pair of non-competing human monoclonal antibodies for clinical development...

In a new study, researchers have investigated the level of induction of immunity from four different types of COVID-19 vaccines. They looked at how T-cells, B-cells, antibody levels change over…

In a recent paper by Markewitz, et al., the researchers aimed to investigate and determine the levels of anti-SARS-CoV-2 antibodies in individuals who have been vaccinated with a mRNA COVID-19…

In a recent study, Wu, et al., aimed to develop a messenger ribonucleic acid (mRNA) vaccine using the SARS-CoV-2 Omicron variant sequence as a target. The aim was to develop…

In a recent study, researchers have demonstrated that the SARS-CoV-2 receptor-binding domain (RBD)-based, sortase A-conjugated nanoparticle (RBD-scNP) vaccine induces neutralizing antibodies (NAbs) in non-human primates (NHPs) against all eight variants of SARS-CoV-2.

8 September 2021 In a recent Pre-print, Keeton et al., examined the effect of prior infection with ancestral (D614G) or Beta variants on Ad26.COV2.S immunogenicity approximately 28 days...

In a recent preprint, Riou and colleagues aimed to provide an overall measure of immune evasion by assessing neutralizing antibody and T cell responses in 44 South African COVID-19 patients…

Researcher aimed to develop a candidate SARS-Cov-2 vaccine that uses the YF17D vaccine as a vector to express a non-cleavable pre-fusion form of the SARS-CoV-2 spike antigen (YF-S0).

There are currently multiple trials that are investigating different strategies such as SARS-CoV-2 vector vaccine prime followed by an mRNA vaccine boost and vice versa. In this summary, we report…

Studies suggest that a single dose of BNT162b2 confers the same benefit as two doses given to those with or without previous SARS-CoV-2 infection; this may be crucial for vaccine…

Moyo-Gwete et al., 2021 demonstrated that 501Y.V2 elicits robust neutralizing antibody responses against both the original variant and 501Y.V3 (P.1), which indicates high levels of cross-reactivity. Watch video summary for..

Multiple studies from South Africa suggest that current SARS-CoV-2 vaccines based on the unmutated virus could have reduced efficacy in protecting against infection by the 501Y.V2 variant. We still need…

Wang et al. demonstrated that mutations found in new SARS-Cov-2 variants can reduce the neutralisation potency of mRNA-COVID-19 vaccinee and convalescent plasma against SARS-CoV-2 pseudo-typed viruses.

Webinar by SA government featuring talks by Professors Shabir Madhi, Glenda Gray and Salim Abdool Karim suggests lower efficacy against the ChAdOx1/nCoV-19 vaccine (22%) but moderate to good efficacy of…

Wu et al. demonstrate that mutations in the B1.1.7 did not affect the neutralisation capacity of mRNA-1273-vaccine induced antibodies, however mutations in the B.1.351 variant drastically reduced the neutralisation capacity…

Interim analysis indicates that vaccine candidate Ad26.COV2.S is safe and immunogenic in both younger and older adults. This finding, in combination with the results in preclinical challenge studies, has supported…

The two doses of mRNA-1273 vaccine showed 94.1% efficacy at preventing COVID-19 illness including severe disease in persons 18 or older. Aside from transient local and systemic reactions, no safety…

This article aims to provide a brief overview of the BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccines efficacy results published in peer-reviewed journals. Both vaccines were tested in young and elderly,…

We have recently provided summaries on BNT162b1, mRNA-1273 and Sputnik V COVID-19 vaccine. This article shall focus on information we have available for ChAdOxnCoV-19, Ad26.COV2.S and Ad5 vector vaccines, CoronaVac…

Overall the vaccine was safe, with the most common systemic and local reactions pain at the injection site, hyperthermia, headache, asthenia, and muscle and joint pain. Immunogenicity results from the…

Interim analysis on 95 cases of which 11 were severe cases all from the placebo group. Preliminary report of their Phase 1 Clinical trial demonstrated that vaccination with mRNA-1273 did not…

BNT162b1 is an mRNA based vaccine, co-developed by Pfizer and BioNTech was the first COVID-19 vaccine to release preliminary analysis that suggests >90% efficacy against COVID-19 infection in SARS-CoV-2-naïve adults.…

Since SARS-CoV-2 is airborne, we would be better served by a vaccine that would be delivered intranasally in order to promote an IgA response that targets the virus at mucosal…

This week we highlight the COVID-19 SIG meeting that featured a talk by Dr Kizzmekia Corbett (NIH) on “SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness. Dr Corbett began her…